MINIMS PHENYLEPHRINE HYDROCHLORIDE

Posology Adults Apply one drop to each eye. If necessary, this dose may be repeated once only, at least one hour after the first drop. 3). There is no data in children aged 12 to 18 years. Phenylephrine is not recommended in these patients.

3). Method of administration The use of a drop of topical anaesthetic a few minutes before instillation of phenylephrine is recommended to prevent stinging.

The frequency of the undesirable effects are not known (cannot be estimated from the available data). Immune System Disorders Hypersensitivity Eye Disorders Eye pain, eye irritation, vision blurred, photophobia, allergic conjunctivitis.

Cardiac disorders Palpitations, tachycardia, extrasystoles, arrhythmias. Arteriospasm coronary, ventricular arrhythmia and myocardial infarction. These sometimes fatal reactions have usually occurred in patients with pre-existing cardiovascular disease.

Vascular disorders Hypertension Paediatric population Respiratory, thoracic and mediastinal disorders Pulmonary oedema Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Use with caution in the presence of diabetes, cerebral arteriosclerosis or long standing bronchial asthma. To reduce the risk of precipitating an attack of narrow angle glaucoma evaluate the anterior chamber angle before use. Ocular hyperaemia can increase the absorption of phenylephrine given topically.

Corneal clouding may occur if phenylephrine 10% is instilled when the corneal epithelium has been denuded or damaged. Systemic absorption may be minimised by compressing the lacrimal sac at the medial canthus for one minute during and after the instillation of the drops.

This blocks the passage of the drops via the naso-lacrimal duct to the wide absorptive area of the nasal and pharyngeal mucosa. Paediatric population Use in children aged below 12 years is contraindicated, since serious systemic adverse reactions have been reported with ophthalmic products containing phenylephrine.

Use in children aged 12 to 18 years is not recommended as adequate clinical experience is missing.

Patients with cardiac disease, hypertension, aneurysms, thyrotoxicosis, long-standing insulin dependent diabetes mellitus and tachycardia. 4). The elderly, because of the increased risk of systemic toxicity. Patients on monoamine oxidase inhibitors, tricyclic anti-depressants and anti-hypertensive agents (including beta-blockers).

Patients with closed angle glaucoma (unless previously treated with iridectomy) and patients with a narrow angle prone to glaucoma precipitated by mydriatics. 1.